Kazia Therapeutics (ASX:KZA) see promising data from Phase 1 ovarian cancer trial
[videojs_hls url=’//du7x25at22z7c.cloudfront.net/297485/index_HLSv3.m3u8′ poster=’http://www.finnewsnetwork.com.au/newssystem/2020/Headlines04_360_201209.jpg’]
Kazia Therapeutics (ASX:KZA) released data from their phase 1 study of Cantrixil in patients with ovarian cancer.
Out of 16 patients, one patient demonstrated a complete response and two patients experienced a partial response according to industry-standard RECIST criteria, making an overall response rate of 19 per cent.
The patient who experienced a complete response remains in remission some three years after her last dose of Cantrixil.
Shares in Kazia Therapeutics (ASX:KZA) are trading 4.4 per cent higher at $1.42.
Copyright 2020 – Finance News Network
Source: Finance News Network